No quarterly revenue total was found in Erasca, Inc.'s SEC filings.
Erasca, Inc. (ERAS) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$27.3 million. As of Jun 30, 2026 it held $384.3 million in cash and investments and $44.7 million in total debt.
Revenue
—
Net income
$-44.08M
-30.1% vs year-ago quarter
Operating cash flow
$-27.27M
-32.8% vs year-ago quarter
Free cash flow
$-27.28M
-32.7% vs year-ago quarter
EPS
$-0.14
-16.7% vs year-ago quarter
Dividend per share
$0.00
Shares outstanding
349.76M
+23.3% vs year-ago quarter
Net cash
$339.56M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ERAS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1761918
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$47.6M | -$187.9M | -$32.6M | -$34.5M | -$38.1M |
| Net income | -$44.1M | -$183.4M | -$29.1M | -$30.6M | -$33.9M |
| Diluted EPS | -$0.14 | -$0.60 | -$0.10 | -$0.11 | -$0.12 |
| Operating cash flow | -$27.3M | -$27.4M | -$21.7M | -$21.7M | -$20.5M |
| Free cash flow | -$27.3M | -$27.4M | -$21.7M | -$21.7M | -$20.6M |
| Total assets | $435.1M | $461.2M | $396.2M | $420.4M | $445.4M |
| Total liabilities | $73.2M | $67.7M | $71.0M | $72.5M | $73.1M |
| Stockholders' equity | $361.9M | $393.5M | $325.2M | $347.9M | $372.3M |
| Cash and investments | $384.3M | $408.5M | $341.8M | $362.4M | $386.7M |
| Total debt | $44.7M | $46.0M | $47.1M | $48.3M | $49.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 16, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Other events
|
Aug 24, 2026 | Aug 24, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Other events
|
Jul 14, 2026 | Jul 13, 2026 |
All 352 Erasca, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.